Literature DB >> 27293816

Bioresorbable drug eluting scaffolds-are bioresorbable stents ready for today's clinical practice?

Christoph Lutter1, Michael Joner1.   

Abstract

Year:  2016        PMID： 27293816      PMCID： PMC4886008          DOI： 10.21037/jtd.2016.04.28

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  8 in total

1.  Drug-eluting stent trials: too much non-inferiority, too little progress?

Authors:  Robert A Byrne; Adnan Kastrati
Journal:  Lancet       Date:  2013-10-31       Impact factor: 79.321

2.  Tools & techniques--statistics: propensity score techniques.

Authors:  Bruno R da Costa; Brigitta Gahl; Peter Jüni
Journal:  EuroIntervention       Date:  2014-10       Impact factor: 6.534

3.  Permanent and biodegradable polymer coatings in the absence of antiproliferative drugs in a porcine model of coronary artery stenting.

Authors:  Tobias Koppara; Eric Wittchow; Robert A Byrne; Gerd Bayer; Tobias Diener; Michael Joner
Journal:  EuroIntervention       Date:  2016-01-22       Impact factor: 6.534

4.  Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).

Authors:  Salvatore Brugaletta; Tommaso Gori; Adrian F Low; Petr Tousek; Eduardo Pinar; Josep Gomez-Lara; Giancarla Scalone; Eberhard Schulz; Mark Y Chan; Viktor Kocka; Jose Hurtado; Juan Antoni Gomez-Hospital; Thomas Münzel; Chi-Hang Lee; Angel Cequier; Mariano Valdés; Petr Widimsky; Patrick W Serruys; Manel Sabaté
Journal:  JACC Cardiovasc Interv       Date:  2015-01       Impact factor: 11.195

Review 5.  Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.

Authors:  Salvatore Cassese; Robert A Byrne; Gjin Ndrepepa; Sebastian Kufner; Jens Wiebe; Janika Repp; Heribert Schunkert; Massimiliano Fusaro; Takeshi Kimura; Adnan Kastrati
Journal:  Lancet       Date:  2015-11-17       Impact factor: 79.321

6.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

Authors:  Stephen G Ellis; Dean J Kereiakes; D Christopher Metzger; Ronald P Caputo; David G Rizik; Paul S Teirstein; Marc R Litt; Annapoorna Kini; Ameer Kabour; Steven O Marx; Jeffrey J Popma; Robert McGreevy; Zhen Zhang; Charles Simonton; Gregg W Stone
Journal:  N Engl J Med       Date:  2015-10-12       Impact factor: 91.245

Review 7.  Bioresorbable scaffolds: rationale, current status, challenges, and future.

Authors:  Javaid Iqbal; Yoshinobu Onuma; John Ormiston; Alexandre Abizaid; Ron Waksman; Patrick Serruys
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

8.  Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.

Authors:  Manel Sabaté; Stephan Windecker; Andres Iñiguez; Lisette Okkels-Jensen; Angel Cequier; Salvatore Brugaletta; Sjoerd H Hofma; Lorenz Räber; Evald Høi Christiansen; Maarten Suttorp; Thomas Pilgrim; Gerrit Anne van Es; Yohei Sotomi; Hector M García-García; Yoshinobu Onuma; Patrick W Serruys
Journal:  Eur Heart J       Date:  2015-09-23       Impact factor: 29.983
  8 in total
  1 in total

Review 1.  Thrombotic responses to coronary stents, bioresorbable scaffolds and the Kounis hypersensitivity-associated acute thrombotic syndrome.

Authors:  Nicholas G Kounis; Ioanna Koniari; Anastasios Roumeliotis; Grigorios Tsigkas; George Soufras; Nicholas Grapsas; Periklis Davlouros; George Hahalis
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.